A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

NCT05367687 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

251

Enrollment

INDUSTRY

Sponsor class

Conditions

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Interventions

DRUG: Camrelizumab、Rivoceranib
DRUG: Camrelizumab

Sponsor

Jiangsu HengRui Medicine Co., Ltd.